|Fastest Growing Market:||Asia Pacific|
|Largest Market:||North America|
Need a report that reflects how COVID-19 has impacted this market and its growth?
The aminoglycosides market was valued at USD 1,673.79 million in 2020, and it is expected to reach USD 2,125.20 million by 2026, registering a CAGR of 4.11% during the forecast period, 2021-2026.
During the current COVID-19 pandemic, prioritizing immunity enhancers is very important in fighting against the disease. For instance, according to a research article by Nehru Sai Suresh Chalichem et al., published in the Medical Hypotheses Journal June 2020, aminoglycosides were found to have defense-mediated antiviral activity, which enhances immunity. Thus, aminoglycosides can be an effective class of drugs against respiratory infection as well as an immunity enhancer for the COVID-19 regimen.
The major factors driving the market growth include the growing instances of animal disease outbreaks, leading to high utilization of antibiotics, rise in the aging population, and increasing prevalence of bacterial infectious diseases.
In humans and animals, the usage of aminoglycosides in the treatment of different bacterial infections is increasing due to the presence of characteristics such as bactericidal activity against staphylococci and certain mycobacteria, which is expected to influence market growth.
Moreover, this class of antibiotics is found to be effective even when bacterial inoculum is large, and it is frequently used as a second line of defense against basic infection resistant to basic antibacterials. The increasing burden of tuberculosis is also expected to drive the demand for aminoglycosides, especially in low-income countries where the incidence is alarmingly high and there is a need for aminoglycosides. For instance, as per the World Health Organization (WHO), in Southeast Asia, there were around 567,000 incident cases of tuberculosis among children in 2019.
Additionally, reduction in the prescription rate of aminoglycoside antibiotics due to side effects associated with the usage of these drugs that include severe ototoxicity, nephrotoxicity, and neuromuscular blockade is expected to affect the market growth negatively.
Scope of the Report
As per the scope of this report, aminoglycosides are highly potent antibiotics with several properties for the treatment of life-threatening infections. Aminoglycosides have concentration-dependent bactericidal activity by binding to the 30S ribosome that inhibits bacterial protein synthesis. The aminoglycosides market is segmented by product (Neomycin, Tobramycin, Gentamycin, Streptomycin, Kanamycin, Paromomycin, Amikacin, Verdamicin, Astromicin, and Hygromycin B), route of administration (parenteral, intra-mammary, topical, and oral), application (veterinary, skin infection, respiratory diseases, UTI and pelvic diseases, and other diseases), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.
|By Route of Administration|
|UTI and Pelvic Diseases|
Key Market Trends
The Gentamicin Segment is Expected to Hold a Significant Market Share Over the Forecast Period
Gentamicin is used in the treatment of serious infections that are caused by bacteria, such as infections of the blood, lungs, bones, joints, skin, and urinary tract and meningitis (infection of the membranes that surround the brain and spinal cord). Gentamicin is the agent of choice for major bacterial infections.
According to the World Health Organization 2020, with an increasing need for extensive research on SARS-CoV-2, the diagnosis of COVID-19 infections relies heavily on the careful and aseptic collection of specimens. In order to collect specimens, a specialized viral transport medium (VTM) is required to protect the virus from environmental damage and maintain its activity with an adequate, sustainable transport system. Adding to that, to avoid contamination, a 0.8 ml Gentamicin sulfate solution has to be used.
In veterinary medicine, drugs such as Gentamicin and Amikacin find maximum usage. Gentamicin is indicated in sepsis, acute/chronic renal disease, diabetes, perinatal complications, labor or neonatal complications, and UTI/pyelonephritis.
For instance, in 2018, Insmed Incorporated received the United States Food and Drug Administration (FDA) approval for ARIKAYCE, an aminoglycoside indicated in adults who have limited or no alternative treatment options for mycobacterium avium complex (MAC) lung disease, as part of a combination antibacterial drug regimen.
According to a research article by Recep Ozturk et al., published in the World Journal of Urology January 2020, globally, urinary tract infections are among the most frequent infections in clinical practice. Community-acquired urinary tract infections (CAUTIs) affect more than 150 million people annually. The high burden of urinary tract infections is expected to increase the use of Gentamicin over the forecast period.
In June 2018, the University of Southern California initiated a clinical trial to assess the safety and efficacy of Gentamicin in the treatment of junctional epidermolysis bullosa.
In both developing and developed markets, Gentamicin forms the first line of treatment for many diseases. The usage of Gentamicin is particularly high in developing regions where it is a cost-effective and efficacious drug for many infectious diseases. Thus, the demand for Gentamicin is consistently growing for different bacterial-related diseases, with several players using it in combinations. Thus, the aforementioned factors are expected to drive the market over the forecast period.
To understand key trends, Download Sample Report
North America is Expected to Hold a Major Market Share Over the Forecast Period
The major factors driving the aminoglycoside market growth include the increasing incidence of bacterial infections, growing demand for early-phase diagnosis and treatment of infectious diseases, and support from the government in the prevention of infection.
According to a research study published in Clinical Infectious Diseases, August 2020, as per data on more than 1,700 hospitalized COVID-19 patients treated at 38 Michigan hospitals in the United States from March 13, 2020, to June 18, 2020, more than half received early antibiotic therapy, with antibiotic use as high as 84% in some hospitals, which shows a positive impact on the market growth.
In 2018, Achaogen Inc. received the United States Food and Drug Administration (FDA) approval for aminoglycoside ZEMDRI (plazomicin), which is indicated for the treatment of patients of 18 years of age or older with complicated urinary tract infections (cUTI), including pyelonephritis.
As per the National Institutes of Health (NIH), in 2019, total infectious diseases funding by the National Institutes for Health in the United States was around USD 6.37 billion, up from USD 6.02 billion in 2018 and USD 6.02 billion in 2017. Thus, increasing funding is expected to drive the demand for aminoglycosides in the prevention of infectious diseases.
According to the 2018 data published by the Centers for Disease Control and Prevention (CDC), the number of deaths caused due to pneumoconiosis among the population aged 15 years and older in the United States was around 1,632. Thus, the increasing burden of infectious diseases is expected to drive the market growth, as this will increase the demand for aminoglycosides in the management of the diseases.
To understand geography trends, Download Sample Report
The aminoglycosides market is moderately fragmented and competitive. The market studied is composed of a large number of players and includes both small and large pharmaceutical manufacturers. Additionally, the increasing antibiotic resistance has prompted many early-stage biotechnology enterprises to enter this market. The expiry of patent exclusivity has led to large-scale generic manufacturing of aminoglycosides, particularly in the developing region of Asia-Pacific. The key market players include Cipla Limited, Pfizer Inc., AbbVie Inc. (Allergan PLC), Teva Pharmaceutical Industries Ltd, and Zoetis Inc., among others.
In March 2021, Major Extremity Trauma Research Consortium planned to initiate a Phase III clinical trial to assess the efficacy of the combination of antibiotics (Tobramycin and vancomycin) in the treatment of post-operative surgical site infection.
In February 2021, Insmed Incorporated initiated a Phase II clinical trial to assess the efficacy of Amikacin liposome inhalation suspension (ALIS)-based regimen in adult subjects with newly diagnosed non-tuberculous mycobacterial lung infection caused by Mycobacterium Avium Complex (MAC).
Table of Contents
1.1 Study Assumptions
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Instances of Animal Disease Outbreaks Leading to High Utilization of Antibiotics
4.2.2 Increase in Aging Population
4.2.3 Increasing Prevalence of Bacterial Infectious Diseases
4.3 Market Restraints
4.3.1 Adverse and Toxic Reactions Associated with Aminoglycosides
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Product
5.1.8 Other Aminoglycosides
5.2 By Route of Administration
5.3 By Application
5.3.2 Skin Infection
5.3.3 Respiratory Diseases
5.3.4 UTI and Pelvic Diseases
5.3.5 Other Diseases
5.4.1 North America
220.127.116.11 United States
18.104.22.168 United Kingdom
22.214.171.124 Rest of Europe
126.96.36.199 South Korea
188.8.131.52 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
184.108.40.206 South Africa
220.127.116.11 Rest of Middle-East and Africa
5.4.5 South America
18.104.22.168 Rest of South America
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 Cipla Limited
6.1.2 Pfizer Inc.
6.1.3 AbbVie Inc. (Allergan PLC)
6.1.4 Novartis AG
6.1.5 Johnson & Johnson
6.1.6 Bristol Myers Squibb Company
6.1.7 Vega Pharma Ltd
6.1.8 Xian Wison Biological Technology Co. Ltd
6.1.9 Yi Chang Veterinary Medicine Factory
6.1.10 Insmed Incorporated
6.1.11 Teva Pharmaceutical Industries Ltd
6.1.12 Achaogen Inc.
6.1.13 Sun Pharmaceutical Industries Limited
6.1.14 Chiesi Farmaceutici
6.1.15 Zoetis Inc.
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Global Aminoglycosides Market market is studied from 2018 - 2026.
What is the growth rate of Global Aminoglycosides Market?
The Global Aminoglycosides Market is growing at a CAGR of 4.11% over the next 5 years.
What is Global Aminoglycosides Market size in 2018?
The Global Aminoglycosides Market is valued at 1673 Million USD in 2018.
What is Global Aminoglycosides Market size in 2026?
The Global Aminoglycosides Market is valued at 2125 Million USD in 2026.
Which region has highest growth rate in Global Aminoglycosides Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Global Aminoglycosides Market?
North America holds highest share in 2020.
Who are the key players in Global Aminoglycosides Market?
Cipla Limited, Pfizer Inc., AbbVie Inc (Allergan Plc), Teva Pharmaceutical Industries Ltd, Zoetis Inc are the major companies operating in Global Aminoglycosides Market.